Objective  To investigate the expression level of lncRNA PCAT19 in gastric cancer tissues and cell lines, and determine its effect and mechanism on the proliferation and apoptosis of gastric cancer cells.

Methods  RT-qPCR was used to detect the expression level of lncRNA PCAT19 in gastric cancer tissues and three gastric cancer cell lines (MKN-45, BGC-823 and MGC-803). The correlation between the expression level of lncRNA PCAT19 in gastric cancer tissues and the clinical pathological characteristics of patients was analyzed. lncRNA PCAT19 expression in MGC-803 cells was interfered by si-PCAT19 transfection, and the changes in the proliferation and apoptosis of cells were investigated using a CCK-8 kit and flow cytometry, respectively. The effect on expression level of proliferation and apoptosis-related proteins was detected by Wstern blot assay.

Results  Compared with adjacent tissues, the expression level of lncRNA PCAT19 in gastric cancer tissues was significantly higher (P<0.05), and its expression level was positively correlated with the degree of gastric cancer invasion (P<0.05). Compared with human gastric mucosal epithelial cells GES-1, the expression levels of lncRNA PCAT19 in three gastric cancer cell lines were significantly higher (P<0.05). Compared with the si-NC group, the proliferation ability of MGC-803 cells in the si-PCAT19 group was reduced (P<0.05), the apoptotic ability was increased (P<0.05), and the expression level of Cyclin D1 was reduced (P<0.05), while the expression level of Caspase-9 was increased (P<0.05).

Conclusion   lncRNA PCAT19 is highly expressed in gastric cancer tissues and cells. Downregulation of lncRNA PCAT19 can inhibit cell proliferation and promote cell apoptosis, which may be related to its regulation of Cyclin D1 and Caspase-9 protein expression.

1.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 60(1): 7-30. DOI: 10.3322/caac.21442.

2.Lyons K, Le LC, Pham YT, et al. Gastric cancer: epidemiology, biology, and prevention: a mini review[J]. Eur J Cancer Prev, 2019, 28(5): 397-412. DOI: 10.1097/CEJ.0000000000000480.

3.左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1): 52-58. [Zuo TT, Zheng RS, Zeng  HM, et al. Epidemiology of stomach cancer in China[J]. Chinese Journal of Clinical Oncology, 2017, 44(1): 52-58.] DOI: 10.3969/j.issn.1000-8179.2017.01.881.

4.王少明, 郑荣寿, 张思维, 等. 2015年中国胃癌流行特征分析[J]. 中华流行病学杂志, 2019, 40(12): 1517-1521. [Wang  SM, Zheng  RS, Zhang SW, et al. Epidemiological characteristics of gastric cancer in China, 2015[J]. Chinese Journal of Epidemiology, 2019, 40(12): 1517-1521.] DOI: 10.3760/cma.j.issn.0254-6450. 2019.12.003.

5.Fang XY, Pan HF, Leng RX, et al. Long noncoding RNAs: novel insights into gastric cancer[J]. Cancer Lett, 2015, 356(2): 357-366. DOI: 10.1016/j.canlet.2014.11.005.

6.李希雯, 罗茜, 鞠少卿. 非编码RNA在胃癌中的研究与应用进展[J]. 临床检验杂志, 2020, 38(3): 207-209. [Li XW, Luo  X, Ju SQ. Research and application of non-coding RNA in gastric cancer[J]. Chinese Journal of Clinical Laboratory Science, 2020, 38(3): 207-209.] DOI: 10.13602/j.cnki.jcls.2020.03.12.

7.孔岳锋, 任立权. miR-206通过靶定Arpc3抑制食管癌细胞的迁移和侵袭[J]. 华中科技大学学报(医学版), 2019, 48(2): 172-176. [Kong YF, Ren LQ. MiR-206 inhibits migration and invasion of esophageal cancer cells by targeting Arpc3[J]. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong, 2019, 48(2): 172-176.] DOI: 10.3870/j.issn.1672-0741.2019.02.008.

8.Zhang R, Xia LQ, Lu WW, et al. LncRNAs and cancer[J]. Oncol Lett, 2016, 12(2): 1233-1239. DOI: 10.3892/ol.2016.4770.

9.Zhang Y, Tang L. The application of lncRNAs in cancer treatment and diagnosis[J]. Recent Pat Anticancer Drug Discov, 2018, 13(3): 292-301. DOI: 10.2174/1574892813666180226121819.

10.Zhang L, Zhou Y, Huang T, et al. The interplay of LncRNA-H19 and its binding partners in physiological process and gastric carcinogenesis[J]. Int J Mol Sci, 2017, 18(2): 450. DOI: 10.3390/ijms18020450.

11.Yörüker EE, Keskin M, Kulle CB, et al. Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer[J]. Biomed Rep, 2018, 9(2): 181-186. DOI: 10.3892/br.2018.1116.

12.Pan W, Liu L, Wei J, et al. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility[J]. Mol Carcinog, 2016, 55(1): 90-96. DOI: 10.1002/mc.22261.

13.Fattahi S, Kosari-Monfared M, Golpour M, et al. LncRNAs as potential diagnostic and prognostic biomarkers in gastric cancer: a novel approach to personalized medicine[J]. J Cell Physiol, 2020, 235(4): 3189-3206. DOI: 10.1002/jcp.29260.

14.Ghafouri-Fard S, Taheri M. Long non-coding RNA signature in gastric cancer[J]. Exp Mol Pathol, 2020, 113: 104365. DOI: 10.1016/j.yexmp.2019.104365.

15.陈超, 张伟丽, 冯长松. lncRNA PCAT19靶向miR-143-3p通过信号通路PI3K/Akt对甲状腺癌细胞增殖和凋亡的影响及机制[J]. 中国老年学杂志, 2020, 40(8): 1712-1717. [Chen C, Zhang  WL, Feng CS. Effect of lncRNA PCAT19 targeting miR-143-3p on proliferation and apoptosis of thyroid cancer cells via signaling pathway PI3K/Akt[J]. Chinese Journal of Gerontology, 2020, 40(8): 1712-1717.] DOI: 10.3969/j.issn.1005-9202.2020.08.043.

16.Xu S, Guo J, Zhang W. lncRNA PCAT19 promotes the proliferation of laryngocarcinoma cells via modulation of the miR-182/PDK4 axis[J]. J Cell Biochem, 2019, 120(8): 12810-12821. DOI: 10.1002/jcb.28552.

17.Xie YH, Hu J. Suppression of long non-coding RNA PCAT19 inhibits glioma cell proliferation and invasion, and increases cell apoptosis through regulation of MELK targeted by miR-142-5p[J]. Genes Genomics, 2020, 42(11): 1299-1310. DOI: 10.1007/s13258-020-01003-w.

18.Zhang X, Wang Q, Xu Y, et al. lncRNA PCAT19 negatively regulates p53 in non-small cell lung cancer[J]. Oncol Lett, 2019, 18(6): 6795-6800. DOI: 10.3892/ol.2019.11041.

19.付春利. lncRNAPCAT19表达下调可抑制肺癌细胞的增值与侵袭[J]. 医药前沿, 2019, 9(20): 106-107. [Fu CL. Down-regulated lncRNAPCAT19 expression can inhibit the proliferation and invasion of lung cancer cells[J]. Journal of Frontiers of Medicine, 2019, 9(20): 106-107.] https://d.wanfangdata.com.cn/periodical/Ch9QZXJpb2RpY2FsQ0hJTmV3UzIwMjUwMTE2MTYzNjE0Eg55aXlxeTIwMTkyMDA3MxoINGVoaXgya3U%3D.

20.侯彬, 黄维平, 尹中普, 等. lncRNA PCAT19吸附miR-142-5p调控ING3基因表达抑制鼻咽癌细胞的增殖和侵袭[J]. 中国临床药理学与治疗学, 2020, 25(7): 721-727. [Hou B, Huang  WP, Yin ZP, et al. lncR NA PCAT19 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells by adsorbing miR-142-5p and regulating the expression of ING3 gene[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 721-727.] DOI: 10.12092/j.issn.1009-2501.2020.07.001.

21.Chiurillo MA. Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review[J]. World J Exp Med, 2015, 5(2): 84-102. DOI: 10.5493/wjem.v5.i2.84.

22.Koushyar S, Powell AG, Vincan E, et al. Targeting Wnt signaling for the treatment of gastric cancer[J]. Int J Mol Sci, 2020, 21(11): 3927. DOI: 10.3390/ijms21113927.

23.Shan YS, Hsu HP, Lai MD, et al. Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer[J]. Oncol Lett, 2017, 14(4): 4517-4526. DOI: 10.3892/ol.2017.6736.

24.Kim B, Srivastava SK, Kim SH. Caspase-9 as a therapeutic target for treating cancer[J]. Expert Opin Ther Targets, 2015, 19(1): 113-127. DOI: 10.1517/14728222.2014.961425.